Hexagon Bio, a Menlo Park, California-based biopharmaceutical company developing cancer treatments using novel antibody-drug conjugate (ADC) payloads, announced the closing of a $62 million Series C funding round on October 23, 2026.
The financing was led by The Column Group, with participation from existing investors Nextech Invest, Deviation Capital, 8VC, and Canada Pension Plan Investment Board (CPP Investments).
Launched in 2017, Hexagon Bio was co-founded by Maureen Hillenmeyer, Brian Naughton, Colin Harvey, and Yi Tang. Hillenmeyer serves as the company’s Chief Executive Officer.
Hexagon Bio develops experimental cancer therapies by identifying naturally occurring compounds encoded in microbial genomes. Its proprietary discovery platform combines genomics, computational biology, and synthetic biology to identify cytotoxic small molecules that can be used as payloads in antibody-drug conjugates.
The company plans to use the new capital to support the Phase 1 clinical trial of HEX-360, its lead drug candidate, with the first-in-human study expected to begin in the first half of 2027.
HEX-360 is a HER2-targeting ADC containing a novel translation inhibitor payload designed to suppress cancer-associated protein production. The experimental therapy is being developed to address resistance mechanisms associated with existing ADC payloads, including topoisomerase inhibitors.
The funding will also support the development of additional payload mechanisms and dual-payload ADC candidates from Hexagon Bio’s discovery platform.
At the American Association for Cancer Research Annual Meeting in 2026, Hexagon Bio presented preclinical data showing antitumor activity for HEX-360, including responses in experimental models resistant to topoisomerase inhibitors. The candidate remained in investigational new drug-enabling studies at the time of the Series C announcement.
Previously, Hexagon Bio raised $77.3 million in a Series B financing announced in February 2023, with participation from The Column Group, Two Sigma Ventures, 8VC, Nextech, and CPP Investments.
